Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 171 entries
Sorted by: Best Match Show Resources per page
TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells.

JCI insight

de Mattos Barbosa MG, Lefferts AR, Huynh D, Liu H, Zhang Y, Fu B, Barnes J, Samaniego M, Bram RJ, Geha RS, Shikanov A, Prak ETL, Farkash EA, Platt JL, Cascalho M.
PMID: 34283811
JCI Insight. 2021 Sep 08;6(17). doi: 10.1172/jci.insight.150483.

Host genes define the severity of inflammation and immunity but specific loci doing so are unknown. Here we show that TNF receptor superfamily member 13B (TNFRSF13B) variants, which enhance defense against certain pathogens, also control immune-mediated injury of transplants,...

Cite
de Mattos Barbosa MG, Lefferts AR, Huynh D, et al. TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight. 2021;6(17)doi: 10.1172/jci.insight.150483.
de Mattos Barbosa, M. G., Lefferts, A. R., Huynh, D., Liu, H., Zhang, Y., Fu, B., Barnes, J., Samaniego, M., Bram, R. J., Geha, R. S., Shikanov, A., Prak, E. T. L., Farkash, E. A., Platt, J. L., & Cascalho, M. (2021). TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI insight, 6(17), . https://doi.org/10.1172/jci.insight.150483
de Mattos Barbosa, Mayara Garcia, et al. "TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells." JCI insight vol. 6,17 (2021). doi: https://doi.org/10.1172/jci.insight.150483
de Mattos Barbosa MG, Lefferts AR, Huynh D, Liu H, Zhang Y, Fu B, Barnes J, Samaniego M, Bram RJ, Geha RS, Shikanov A, Prak ETL, Farkash EA, Platt JL, Cascalho M. TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight. 2021 Sep 08;6(17). doi: 10.1172/jci.insight.150483. PMID: 34283811; PMCID: PMC8492324.
Copy Download .nbib Format: NLM
The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma.

Cancers

Faict S, Oudaert I, D'Auria L, Dehairs J, Maes K, Vlummens P, De Veirman K, De Bruyne E, Fostier K, Vande Broek I, Schots R, Vanderkerken K, Swinnen JV, Menu E.
PMID: 31756922
Cancers (Basel). 2019 Nov 20;11(12). doi: 10.3390/cancers11121823.

Multiple myeloma (MM) is well-known for the development of drug resistance, leading to relapse. Therefore, finding novel treatment strategies remains necessary. By performing a lipidomics assay on MM patient plasma, we aimed to identify new targets. We observed a...

Cite
Faict S, Oudaert I, D'Auria L, et al. The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. Cancers (Basel). 2019;11(12)doi: 10.3390/cancers11121823.
Faict, S., Oudaert, I., D'Auria, L., Dehairs, J., Maes, K., Vlummens, P., De Veirman, K., De Bruyne, E., Fostier, K., Vande Broek, I., Schots, R., Vanderkerken, K., Swinnen, J. V., & Menu, E. (2019). The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. Cancers, 11(12), . https://doi.org/10.3390/cancers11121823
Faict, Sylvia, et al. "The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma." Cancers vol. 11,12 (2019). doi: https://doi.org/10.3390/cancers11121823
Faict S, Oudaert I, D'Auria L, Dehairs J, Maes K, Vlummens P, De Veirman K, De Bruyne E, Fostier K, Vande Broek I, Schots R, Vanderkerken K, Swinnen JV, Menu E. The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. Cancers (Basel). 2019 Nov 20;11(12). doi: 10.3390/cancers11121823. PMID: 31756922; PMCID: PMC6966559.
Copy Download .nbib Format: NLM
A nano based approach to alleviate cisplatin induced nephrotoxicity.

International journal of immunopathology and pharmacology

Anees LM, Abdel-Hamid GR, Elkady AA.
PMID: 34915755
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211066441. doi: 10.1177/20587384211066441.

BACKGROUND AND OBJECTIVE: Cisplatin, an effective drug against cancer, commonly induces nephrotoxicity; limiting its therapeutic efficacy and application. In this study, Cisplatin NanoComposite (Cis NC) was formulated successfully from irradiated chitosan coated Cisplatin and MgO nanoparticles (CHIT/Cis/MgO NPs) to...

Cite
Anees LM, Abdel-Hamid GR, Elkady AA. A nano based approach to alleviate cisplatin induced nephrotoxicity. Int J Immunopathol Pharmacol. 2021;35:20587384211066441doi: 10.1177/20587384211066441.
Anees, L. M., Abdel-Hamid, G. R., & Elkady, A. A. (2021). A nano based approach to alleviate cisplatin induced nephrotoxicity. International journal of immunopathology and pharmacology, 3520587384211066441. https://doi.org/10.1177/20587384211066441
Anees, Lobna M, et al. "A nano based approach to alleviate cisplatin induced nephrotoxicity." International journal of immunopathology and pharmacology vol. 35 (2021): 20587384211066441. doi: https://doi.org/10.1177/20587384211066441
Anees LM, Abdel-Hamid GR, Elkady AA. A nano based approach to alleviate cisplatin induced nephrotoxicity. Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211066441. doi: 10.1177/20587384211066441. PMID: 34915755.
Copy Download .nbib Format: NLM
Impact Toughness of Hybrid Carbon Fiber-PLA/ABS Laminar Composite Produced through Fused Filament Fabrication.

Polymers

Ahmed H, Hussain G, Gohar S, Ali A, Alkahtani M.
PMID: 34577956
Polymers (Basel). 2021 Sep 10;13(18). doi: 10.3390/polym13183057.

Nowadays, the components of carbon fiber-reinforced polymer composites (an important material) are directly produced with 3D printing technology, especially Fused Filament Fabrication (FFF). However, such components suffer from poor toughness. The main aim of this research is to overcome...

Cite
Ahmed H, Hussain G, Gohar S, et al. Impact Toughness of Hybrid Carbon Fiber-PLA/ABS Laminar Composite Produced through Fused Filament Fabrication. Polymers (Basel). 2021;13(18)doi: 10.3390/polym13183057.
Ahmed, H., Hussain, G., Gohar, S., Ali, A., & Alkahtani, M. (2021). Impact Toughness of Hybrid Carbon Fiber-PLA/ABS Laminar Composite Produced through Fused Filament Fabrication. Polymers, 13(18), . https://doi.org/10.3390/polym13183057
Ahmed, Hafiz, et al. "Impact Toughness of Hybrid Carbon Fiber-PLA/ABS Laminar Composite Produced through Fused Filament Fabrication." Polymers vol. 13,18 (2021). doi: https://doi.org/10.3390/polym13183057
Ahmed H, Hussain G, Gohar S, Ali A, Alkahtani M. Impact Toughness of Hybrid Carbon Fiber-PLA/ABS Laminar Composite Produced through Fused Filament Fabrication. Polymers (Basel). 2021 Sep 10;13(18). doi: 10.3390/polym13183057. PMID: 34577956; PMCID: PMC8468235.
Copy Download .nbib Format: NLM
Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.

Hepatology (Baltimore, Md.)

Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, Chu R, Micolochick Steuer H, Lehar S, Peiser L, Palazzo A, Frey C, Davies J, Javanbakht H, Rosenberg WMC, Fletcher SP, Maini MK, Pallett LJ.
PMID: 33368377
Hepatology. 2021 Jul;74(1):55-71. doi: 10.1002/hep.31695. Epub 2021 Jun 20.

BACKGROUND AND AIMS: GS-9688 (selgantolimod) is a toll-like receptor 8 agonist in clinical development for the treatment of chronic hepatitis B (CHB). Antiviral activity of GS-9688 has previously been evaluated in vitro in HBV-infected hepatocytes and in vivo in...

Cite
Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. Hepatology. 2021;74(1):55-71doi: 10.1002/hep.31695.
Amin, O. E., Colbeck, E. J., Daffis, S., Khan, S., Ramakrishnan, D., Pattabiraman, D., Chu, R., Micolochick Steuer, H., Lehar, S., Peiser, L., Palazzo, A., Frey, C., Davies, J., Javanbakht, H., Rosenberg, W. M. C., Fletcher, S. P., Maini, M. K., & Pallett, L. J. (2021). Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. Hepatology (Baltimore, Md.), 74(1), 55-71. https://doi.org/10.1002/hep.31695
Amin, Oliver E, et al. "Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators." Hepatology (Baltimore, Md.) vol. 74,1 (2021): 55-71. doi: https://doi.org/10.1002/hep.31695
Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, Chu R, Micolochick Steuer H, Lehar S, Peiser L, Palazzo A, Frey C, Davies J, Javanbakht H, Rosenberg WMC, Fletcher SP, Maini MK, Pallett LJ. Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators. Hepatology. 2021 Jul;74(1):55-71. doi: 10.1002/hep.31695. Epub 2021 Jun 20. PMID: 33368377; PMCID: PMC8436741.
Copy Download .nbib Format: NLM
TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells.

JCI insight

de Mattos Barbosa MG, Lefferts AR, Huynh D, Liu H, Zhang Y, Fu B, Barnes J, Samaniego M, Bram RJ, Geha RS, Shikanov A, Prak ETL, Farkash EA, Platt JL, Cascalho M.
PMID: 34283811
JCI Insight. 2021 Sep 08;6(17). doi: 10.1172/jci.insight.150483.

Host genes define the severity of inflammation and immunity but specific loci doing so are unknown. Here we show that TNF receptor superfamily member 13B (TNFRSF13B) variants, which enhance defense against certain pathogens, also control immune-mediated injury of transplants,...

Cite
de Mattos Barbosa MG, Lefferts AR, Huynh D, et al. TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight. 2021;6(17)doi: 10.1172/jci.insight.150483.
de Mattos Barbosa, M. G., Lefferts, A. R., Huynh, D., Liu, H., Zhang, Y., Fu, B., Barnes, J., Samaniego, M., Bram, R. J., Geha, R. S., Shikanov, A., Prak, E. T. L., Farkash, E. A., Platt, J. L., & Cascalho, M. (2021). TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI insight, 6(17), . https://doi.org/10.1172/jci.insight.150483
de Mattos Barbosa, Mayara Garcia, et al. "TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells." JCI insight vol. 6,17 (2021). doi: https://doi.org/10.1172/jci.insight.150483
de Mattos Barbosa MG, Lefferts AR, Huynh D, Liu H, Zhang Y, Fu B, Barnes J, Samaniego M, Bram RJ, Geha RS, Shikanov A, Prak ETL, Farkash EA, Platt JL, Cascalho M. TNFRSF13B genotypes control immune-mediated pathology by regulating the functions of innate B cells. JCI Insight. 2021 Sep 08;6(17). doi: 10.1172/jci.insight.150483. PMID: 34283811; PMCID: PMC8492324.
Copy Download .nbib Format: NLM
Application of metabolomics in drug resistant breast cancer research.

Metabolites

Shajahan-Haq AN, Cheema MS, Clarke R.
PMID: 25693144
Metabolites. 2015 Feb 16;5(1):100-18. doi: 10.3390/metabo5010100.

The metabolic profiles of breast cancer cells are different from normal mammary epithelial cells. Breast cancer cells that gain resistance to therapeutic interventions can reprogram their endogenous metabolism in order to adapt and proliferate despite high oxidative stress and...

Cite
Shajahan-Haq AN, Cheema MS, Clarke R. Application of metabolomics in drug resistant breast cancer research. Metabolites. 2015;5(1):100-18doi: 10.3390/metabo5010100.
Shajahan-Haq, A. N., Cheema, M. S., & Clarke, R. (2015). Application of metabolomics in drug resistant breast cancer research. Metabolites, 5(1), 100-18. https://doi.org/10.3390/metabo5010100
Shajahan-Haq, Ayesha N, et al. "Application of metabolomics in drug resistant breast cancer research." Metabolites vol. 5,1 (2015): 100-18. doi: https://doi.org/10.3390/metabo5010100
Shajahan-Haq AN, Cheema MS, Clarke R. Application of metabolomics in drug resistant breast cancer research. Metabolites. 2015 Feb 16;5(1):100-18. doi: 10.3390/metabo5010100. PMID: 25693144; PMCID: PMC4381292.
Copy Download .nbib Format: NLM
Improvement in the Prognosis of Patients With Acute Myocardial Infarction in the 1990s Compared With the Prethrombolytic Era: An Analysis by Age Subgroups.

The American journal of geriatric cardiology

Gottlieb S, Goldbourt U, Boyko V, Barbash G, Mandelzweig L, Behar S.
PMID: 11416352
Am J Geriatr Cardiol. 1995 Nov;4(6):17-31.

The number of elderly patients experiencing myocardial infarction (MI) is growing rapidly, and their hospital mortality rate remains high, although mortality after acute MI declined in the 1990s. The in-hospital and first-year mortality rates in 5,839 patients with acute...

Cite
Gottlieb S, Goldbourt U, Boyko V, et al. Improvement in the Prognosis of Patients With Acute Myocardial Infarction in the 1990s Compared With the Prethrombolytic Era: An Analysis by Age Subgroups. Am J Geriatr Cardiol. 1995;4(6):17-31
Gottlieb, S., Goldbourt, U., Boyko, V., Barbash, G., Mandelzweig, L., & Behar, S. (1995). Improvement in the Prognosis of Patients With Acute Myocardial Infarction in the 1990s Compared With the Prethrombolytic Era: An Analysis by Age Subgroups. The American journal of geriatric cardiology, 4(6), 17-31.
Gottlieb, Shmuel, et al. "Improvement in the Prognosis of Patients With Acute Myocardial Infarction in the 1990s Compared With the Prethrombolytic Era: An Analysis by Age Subgroups." The American journal of geriatric cardiology vol. 4,6 (1995): 17-31.
Gottlieb S, Goldbourt U, Boyko V, Barbash G, Mandelzweig L, Behar S. Improvement in the Prognosis of Patients With Acute Myocardial Infarction in the 1990s Compared With the Prethrombolytic Era: An Analysis by Age Subgroups. Am J Geriatr Cardiol. 1995 Nov;4(6):17-31. PMID: 11416352.
Copy Download .nbib Format: NLM
Allergy, a disease of the internal and external environments.

Current opinion in immunology

Geha RS.
PMID: 11102762
Curr Opin Immunol. 2000 Dec;12(6):615-7. doi: 10.1016/s0952-7915(00)00152-7.

No abstract available.

Cite
Geha RS. Allergy, a disease of the internal and external environments. Curr Opin Immunol. 2000;12(6):615-7doi: 10.1016/s0952-7915(00)00152-7.
Geha, R. S. (2000). Allergy, a disease of the internal and external environments. Current opinion in immunology, 12(6), 615-7. https://doi.org/10.1016/s0952-7915(00)00152-7
Geha. "Allergy, a disease of the internal and external environments." Current opinion in immunology vol. 12,6 (2000): 615-7. doi: https://doi.org/10.1016/s0952-7915(00)00152-7
Geha RS. Allergy, a disease of the internal and external environments. Curr Opin Immunol. 2000 Dec;12(6):615-7. doi: 10.1016/s0952-7915(00)00152-7. PMID: 11102762.
Copy Download .nbib Format: NLM
Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from .

Antioxidants (Basel, Switzerland)

Saleem F, Mehmood R, Mehar S, Khan MTJ, Khan ZU, Ashraf M, Ali MS, Abdullah I, Froeyen M, Mirza MU, Ahmad S.
PMID: 31331076
Antioxidants (Basel). 2019 Jul 19;8(7). doi: 10.3390/antiox8070231.

Members of genus

Cite
Saleem F, Mehmood R, Mehar S, et al. Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from . Antioxidants (Basel). 2019;8(7)doi: 10.3390/antiox8070231.
Saleem, F., Mehmood, R., Mehar, S., Khan, M. T. J., Khan, Z. U., Ashraf, M., Ali, M. S., Abdullah, I., Froeyen, M., Mirza, M. U., & Ahmad, S. (2019). Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from . Antioxidants (Basel, Switzerland), 8(7), . https://doi.org/10.3390/antiox8070231
Saleem, Farooq, et al. "Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from ." Antioxidants (Basel, Switzerland) vol. 8,7 (2019). doi: https://doi.org/10.3390/antiox8070231
Saleem F, Mehmood R, Mehar S, Khan MTJ, Khan ZU, Ashraf M, Ali MS, Abdullah I, Froeyen M, Mirza MU, Ahmad S. Bioassay Directed Isolation, Biological Evaluation and in Silico Studies of New Isolates from . Antioxidants (Basel). 2019 Jul 19;8(7). doi: 10.3390/antiox8070231. PMID: 31331076; PMCID: PMC6680627.
Copy Download .nbib Format: NLM
The Future Comes Early for Medical Educators.

Journal of general internal medicine

Minter DJ, Geha R, Manesh R, Dhaliwal G.
PMID: 32875502
J Gen Intern Med. 2021 May;36(5):1400-1403. doi: 10.1007/s11606-020-06128-y. Epub 2020 Sep 01.

Many experts have foretold of a digital transformation in medical education. Yet, until recently, day-to-day practices for frontline clinician-educators, who cherish close physical and intellectual contact between the patient, learner, and teacher, have remained largely unchanged. The COVID-19 pandemic...

Cite
Minter DJ, Geha R, Manesh R, et al. The Future Comes Early for Medical Educators. J Gen Intern Med. 2020;36(5):1400-1403doi: 10.1007/s11606-020-06128-y.
Minter, D. J., Geha, R., Manesh, R., & Dhaliwal, G. (2021). The Future Comes Early for Medical Educators. Journal of general internal medicine, 36(5), 1400-1403. https://doi.org/10.1007/s11606-020-06128-y
Minter, Daniel J, et al. "The Future Comes Early for Medical Educators." Journal of general internal medicine vol. 36,5 (2021): 1400-1403. doi: https://doi.org/10.1007/s11606-020-06128-y
Minter DJ, Geha R, Manesh R, Dhaliwal G. The Future Comes Early for Medical Educators. J Gen Intern Med. 2021 May;36(5):1400-1403. doi: 10.1007/s11606-020-06128-y. Epub 2020 Sep 01. PMID: 32875502; PMCID: PMC7462356.
Copy Download .nbib Format: NLM
More Is Less.

Journal of hospital medicine

Chan H, Nematollahi S, Manesh R, Geha RM, Minter DJ.
PMID: 32966193
J Hosp Med. 2021 Apr;16(4):239-243. doi: 10.12788/jhm.3488.

No abstract available.

Cite
Chan H, Nematollahi S, Manesh R, et al. More Is Less. J Hosp Med. 2021;16(4):239-243doi: 10.12788/jhm.3488.
Chan, H., Nematollahi, S., Manesh, R., Geha, R. M., & Minter, D. J. (2021). More Is Less. Journal of hospital medicine, 16(4), 239-243. https://doi.org/10.12788/jhm.3488
Chan, Hilary, et al. "More Is Less." Journal of hospital medicine vol. 16,4 (2021): 239-243. doi: https://doi.org/10.12788/jhm.3488
Chan H, Nematollahi S, Manesh R, Geha RM, Minter DJ. More Is Less. J Hosp Med. 2021 Apr;16(4):239-243. doi: 10.12788/jhm.3488. PMID: 32966193.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 171 entries